Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Expert Opinion on Therapeutic Targets|June 14, 2005
ED-B fibronectin as a target for antibody-based cancer treatmentsAndreas Menrad, Hans D MenssenInternational Journal of Hematology|September 7, 2002
Wilms tumor gene (WT1) expression as a panleukemic markerHans D Menssen, Jan M Siehl, Eckhard ThielClinical Pharmacology in Drug Development|July 31, 2018
Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy VolunteersHans D Menssen, Michelle Quinlan, Charisse Kemp, et al.Cancer Chemotherapy and Pharmacology|August 7, 2024
Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurinRomain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, et al.Journal of Cancer Research and Clinical Oncology|January 13, 2018
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma modelHans D Menssen, Ulf Harnack, Ulrike Erben, et al.Annals of Hematology|September 2, 2004
Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variantsJan M Siehl, Mark Reinwald, Karin Heufelder, et al.Gynecologic Oncology|September 1, 2009
A review of the current evidence for maintenance therapy in ovarian cancerTalia Foster, T Michelle Brown, Jane Chang, et al.Cancer Chemotherapy and Pharmacology|January 25, 2024
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participantsRomain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, et al.Journal of Cancer Research and Clinical Oncology|October 18, 2013
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patientRicarda Locher, Paola A Erba, Burkhard Hirsch, et al.European Journal of Cancer (Oxford, England : 1990)|March 15, 2011
Microvascular biodistribution of L19-SIP in angiogenesis targeting strategiesMarcus Czabanka, Güliz Parmaksiz, Simon H Bayerl, et al.Pageof 4